{"id":745401,"date":"2016-03-30T06:00:00","date_gmt":"2016-03-30T06:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-findings-from-chronic-hepatitis-c-clinical-development-programs-at-the-international-liver-congresstm-2016\/"},"modified":"2025-11-07T01:25:56","modified_gmt":"2025-11-07T06:25:56","slug":"merck-to-present-new-findings-from-chronic-hepatitis-c-clinical-development-programs-at-the-international-liver-congresstm-2016","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-findings-from-chronic-hepatitis-c-clinical-development-programs-at-the-international-liver-congresstm-2016\/","title":{"rendered":"Merck to Present New Findings from Chronic Hepatitis C Clinical Development Programs at The International Liver CongressTM 2016"},"content":{"rendered":"<p class=\"bwalignc\">       Presentations Include Results from Phase 3 Study Evaluating ZEPATIER\u2122        (elbasvir and grazoprevir) Compared to Sofosbuvir-Containing Regimen,        and Results from Studies in Difficult-to-Treat Populations     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside of the United States and Canada,<br \/>\n      today announced the planned presentations of data from the company\u2019s<br \/>\n      broad chronic hepatitis C virus (HCV) clinical development programs at<br \/>\n      the upcoming <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Filc-congress.eu%2F&amp;esheet=51309121&amp;newsitemid=20160330005116&amp;lan=en-US&amp;anchor=International+Liver+Congress%E2%84%A2+2016&amp;index=1&amp;md5=4fbeb9ec76b044353f31c096d622ce3c\" rel=\"nofollow\">International<br \/>\n      Liver Congress\u2122 2016<\/a>. Clinical data from trials evaluating ZEPATIER\u2122<br \/>\n      (elbasvir and grazoprevir) 50mg\/100mg tablets will be featured,<br \/>\n      including the Phase 3 <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02358044&amp;esheet=51309121&amp;newsitemid=20160330005116&amp;lan=en-US&amp;anchor=C-EDGE+Head-to-Head&amp;index=2&amp;md5=f49f5ce2f79d55a6670c7863bcd986c5\" rel=\"nofollow\"><i>C-EDGE<br \/>\n      Head-to-Head<\/i><\/a> trial comparing ZEPATIER to a regimen of sofosbuvir<br \/>\n      with peginterferon alfa and ribavirin (RBV), and the Phase 3 <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02252016&amp;esheet=51309121&amp;newsitemid=20160330005116&amp;lan=en-US&amp;anchor=C-EDGE+IBLD&amp;index=3&amp;md5=68c1967297fd25fba89910336cfb0cec\" rel=\"nofollow\"><i>C-EDGE<br \/>\n      IBLD<\/i><\/a> and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02105688&amp;esheet=51309121&amp;newsitemid=20160330005116&amp;lan=en-US&amp;anchor=C-EDGE+CO-STAR&amp;index=4&amp;md5=9e2bec6511985143e08aa46f45a6dfc3\" rel=\"nofollow\"><i>C-EDGE<br \/>\n      CO-STAR<\/i><\/a> studies evaluating ZEPATIER in underserved patients with<br \/>\n      historically difficult-to-treat conditions. In addition, data from<br \/>\n      trials evaluating Merck\u2019s chronic HCV candidates MK-3682B<br \/>\n      (grazoprevir\/MK-8408<sup>1<\/sup>\/MK-3682<sup>2<\/sup>) and MK-8408<br \/>\n      monotherapy will be presented. ZEPATIER \u2013 Merck\u2019s once-daily, fixed-dose<br \/>\n      combination tablet indicated with or without RBV for the treatment of<br \/>\n      chronic HCV genotype (GT) 1 or GT4 infection in adults \u2013 was approved by<br \/>\n      the U.S. Food and Drug Administration (FDA) on Jan. 28, 2016. The<br \/>\n      International Liver Congress\u2122 2016 is scheduled to take place at the<br \/>\n      Fira Barcelona Gran Via, Barcelona, Spain from April 13-17, 2016.\n    <\/p>\n<p>\n      \u201cWe continue to build on the data that supported the recent U.S. FDA<br \/>\n      approval of ZEPATIER with additional studies that provide clinical<br \/>\n      evidence about ZEPATIER in multiple patient populations,\u201d said Dr. Eliav<br \/>\n      Barr, vice president, infectious diseases, Merck Research Laboratories.<br \/>\n      \u201cMerck remains committed to the fight against chronic hepatitis C<br \/>\n      through our ongoing clinical programs exploring diverse patient groups<br \/>\n      and areas of unmet need.\u201d\n    <\/p>\n<p>\n      At The International Liver Congress\u2122 2016, key data presentations will<br \/>\n      include:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        New data from the Phase 3 <i>C-EDGE<\/i> clinical trial program,<br \/>\n        evaluating ZEPATIER (elbasvir and grazoprevir) (with or without RBV),<br \/>\n        across multiple HCV genotypes (1, 4 and 6) and diverse patient<br \/>\n        populations, including those who are historically difficult-to-treat,<br \/>\n        over a 12-week treatment duration.\n      <\/li>\n<\/ul>\n<p class=\"bwmarginl1\">\n      <span class=\"bwuline\">Thursday, April 14:<\/span>\n    <\/p>\n<ul class=\"bwmarginl1\">\n<li class=\"bwlistitemmargb\">\n        <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02358044&amp;esheet=51309121&amp;newsitemid=20160330005116&amp;lan=en-US&amp;anchor=C-EDGE+Head-to-Head+%28H2H%29&amp;index=5&amp;md5=a3480771ac3ac3e2db9adc1e4e4261de\" rel=\"nofollow\"><i>C-EDGE<\/i><br \/>\n        <i>Head-to-Head (H2H)<\/i><\/a>: Efficacy and Safety of Elbasvir and<br \/>\n        Grazoprevir Compared With Sofosbuvir\/Pegylated Interferon\/Ribavirin: A<br \/>\n        Phase 3 Randomized Controlled Trial (Oral presentation, Abstract<br \/>\n        #PS002, 4:15 p.m.-4:30 p.m. CEST)\n      <\/li>\n<\/ul>\n<ul class=\"bwmarginl1\">\n<li class=\"bwlistitemmargb\">\n        <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02105688&amp;esheet=51309121&amp;newsitemid=20160330005116&amp;lan=en-US&amp;anchor=C-EDGE+CO-STAR&amp;index=6&amp;md5=5e2e25736e09f7fbe4452fd8c8d3df75\" rel=\"nofollow\"><i>C-EDGE<br \/>\n        CO-STAR<\/i><\/a><i>:<\/i> Favorable Impact of Elbasvir and Grazoprevir<br \/>\n        on Health-Related Quality of Life in Treatment-Na\u00efve HCV-Infected<br \/>\n        Persons Who Inject Drugs Receiving Opioid Agonist Therapy (Poster<br \/>\n        presentation, Abstract #THU-225, 8:00 a.m.-6:00 p.m. CEST)\n      <\/li>\n<\/ul>\n<p class=\"bwmarginl1\">\n      <span class=\"bwuline\">Saturday, April 16:<\/span>\n    <\/p>\n<ul class=\"bwmarginl1\">\n<li class=\"bwlistitemmargb\">\n        <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02252016&amp;esheet=51309121&amp;newsitemid=20160330005116&amp;lan=en-US&amp;anchor=C-EDGE+IBLD&amp;index=7&amp;md5=edc9a5d93c2ad08981872a840c5653d3\" rel=\"nofollow\"><i>C-EDGE<br \/>\n        IBLD<\/i><\/a>: Efficacy and Safety of Elbasvir\/Grazoprevir (EBR\/GZR) in<br \/>\n        Subjects With Chronic Hepatitis C Virus Infection and Inherited Blood<br \/>\n        Disorders (IBLD) (Poster presentation, Abstract #SAT-128, 8:00<br \/>\n        a.m.-6:00 p.m. CEST)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02105467&amp;esheet=51309121&amp;newsitemid=20160330005116&amp;lan=en-US&amp;anchor=C-EDGE+TN&amp;index=8&amp;md5=aa157e7a39ee7e8b9d9c29dca4f5f210\" rel=\"nofollow\"><i>C-EDGE<br \/>\n        TN<\/i><\/a><i>: <\/i>Final SVR24 Data From the Phase 3 <i>C-EDGE<\/i> <i>Treatment-Na\u00efve<br \/>\n        (TN)<\/i> Study of Elbasvir (EBR)\/Grazoprevir (GZR) in Patients With<br \/>\n        Chronic HCV Genotype 1, 4 or 6 Infection (Poster presentation,<br \/>\n        Abstract #SAT-266, 8:00 a.m.-6:00 p.m. CEST)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02105688&amp;esheet=51309121&amp;newsitemid=20160330005116&amp;lan=en-US&amp;anchor=C-EDGE+CO-STAR&amp;index=9&amp;md5=5eda53e058106aeed4b4a24c99cd4ae7\" rel=\"nofollow\"><i>C-EDGE<br \/>\n        CO-STAR<\/i><\/a><i>:<\/i> Risk of Reinfection Following Successful<br \/>\n        Therapy With Elbasvir and Grazoprevir in Persons Who Inject Drugs<br \/>\n        (PWID) Receiving Opioid Agonist Therapy (OAT) (Poster presentation,<br \/>\n        Abstract #SAT-163, 8:00 a.m.-6:00 p.m. CEST)\n      <\/li>\n<\/ul>\n<p>\n      <b>Additional Presentations of Interest<\/b>\n    <\/p>\n<p>\n      <span class=\"bwuline\">Thursday, April 14:<\/span>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        In a 5-Day Monotherapy Trial, MK-8408 Demonstrates Potent Antiviral<br \/>\n        Activity and Improved Resistance Profile in HCV Patients With<br \/>\n        Genotypes 1, 2, and 3 Infections (Poster presentation, Abstract<br \/>\n        #THU-222, 8:00 a.m.-6:00 p.m. CEST)\n      <\/li>\n<\/ul>\n<p>\n      <span class=\"bwuline\">Saturday, April 16:<\/span>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        High Efficacy of an 8-Week 3-Drug Regimen of<br \/>\n        Grazoprevir\/MK-8408\/MK-3682 in HCV Genotype 1, 2 and 3-Infected<br \/>\n        Patients: SVR24 Data From the Phase 2 <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02332707&amp;esheet=51309121&amp;newsitemid=20160330005116&amp;lan=en-US&amp;anchor=C-CREST+1&amp;index=10&amp;md5=73aad75ce024dcab2c657eae791939e0\" rel=\"nofollow\"><i>C-CREST<br \/>\n        1<\/i><\/a><i> <\/i>and<i> <\/i><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02332720&amp;esheet=51309121&amp;newsitemid=20160330005116&amp;lan=en-US&amp;anchor=2&amp;index=11&amp;md5=efe2bcdd33e626b14a0eaf2586cc980a\" rel=\"nofollow\"><i>2<\/i><\/a><br \/>\n        Studies (Poster presentation, Abstract #SAT-139, 8:00 a.m.-6:00 p.m.<br \/>\n        CEST)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02133131&amp;esheet=51309121&amp;newsitemid=20160330005116&amp;lan=en-US&amp;anchor=C-SWIFT&amp;index=12&amp;md5=9639b2f1d1cc2fd11ec06aab36e69b6a\" rel=\"nofollow\"><i>C-SWIFT<\/i><\/a><i><br \/>\n        <\/i>Retreatment Final Results: Highly Successful Retreatment of<br \/>\n        GT1-Infected Patients With 12 Weeks of Elbasvir\/Grazoprevir Plus<br \/>\n        Sofosbuvir and Ribavirin After Failure of Short-Duration All-Oral<br \/>\n        Therapy (Poster presentation, Abstract #SAT-148, 8:00 a.m.-6:00 p.m.<br \/>\n        CEST)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Cost Effectiveness of Elbasvir (EBS, MK-8742)\/Grazoprevir<br \/>\n        (GZR\/MK-5172) Use in Treatment-Na\u00efve and Treatment-Experienced<br \/>\n        Patients With Hepatitis C Virus (HCV) Genotype 1 Infection and Chronic<br \/>\n        Kidney Disease (CKD) in the United States (Poster presentation,<br \/>\n        Abstract #SAT-141, 8:00 a.m.-6:00 p.m. CEST)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Sustained Virologic Response Among Patients With Genotype 1 Hepatitis<br \/>\n        C and Treated With Interferon-Free Direct-Acting Antiviral Regimens<br \/>\n        (Poster presentation, Abstract #SAT-217, 8:00 a.m.-6:00 p.m. CEST)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Characteristics and Prevalence of Chronic Kidney Disease Among<br \/>\n        Patients With Hepatitis C Who Are Treated With Interferon-Free<br \/>\n        Direct-Acting Antiviral Regimens (Poster presentation, Abstract<br \/>\n        #SAT-109, 8:00 a.m.-6:00 p.m. CEST)\n      <\/li>\n<\/ul>\n<p>\n      For more information, including a complete list of abstract titles at<br \/>\n      the meeting, please visit: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Filc-congress.eu%2F&amp;esheet=51309121&amp;newsitemid=20160330005116&amp;lan=en-US&amp;anchor=http%3A%2F%2Filc-congress.eu%2F&amp;index=13&amp;md5=30b836e1cfa675c3b7faa8a5cb1deb19\" rel=\"nofollow\">http:\/\/ilc-congress.eu\/<\/a>.\n    <\/p>\n<p>\n      <b>Selected Safety Information about ZEPATIER (elbasvir and grazoprevir)<\/b>\n    <\/p>\n<p>\n      ZEPATIER is not for use in patients with moderate or severe hepatic<br \/>\n      impairment (Child Pugh B or C). ZEPATIER is also not for use with<br \/>\n      organic anion transporting polypeptides 1B1\/3 (OATP1B1\/3) inhibitors<br \/>\n      (e.g., atazanavir, darunavir, lopinavir, saquinavir, tipranavir,<br \/>\n      cyclosporine), strong cytochrome P450 3A (CYP3A) inducers (e.g.,<br \/>\n      carbamazepine, phenytoin, rifampin, St. John\u2019s Wort), and efavirenz. If<br \/>\n      ZEPATIER (elbasvir and grazoprevir) is administered with ribavirin<br \/>\n      (RBV), healthcare professionals should refer to the prescribing<br \/>\n      information for RBV as the contraindications, warnings and precautions,<br \/>\n      adverse reactions and dosing for RBV also apply to this combination<br \/>\n      regimen.\n    <\/p>\n<p>\n      Elevations of alanine transaminase (ALT) to greater than 5 times the<br \/>\n      upper limit of normal (ULN) occurred in 1% of subjects, generally at or<br \/>\n      after treatment week 8. These late ALT elevations were typically<br \/>\n      asymptomatic and most resolved with ongoing or completion of therapy.<br \/>\n      Healthcare professionals should perform hepatic lab testing on patients<br \/>\n      prior to therapy, at treatment week 8, and as clinically indicated. For<br \/>\n      patients receiving 16 weeks of therapy, additional hepatic lab testing<br \/>\n      should be performed at treatment week 12.\n    <\/p>\n<p>\n      Patients should be instructed to consult their healthcare professional<br \/>\n      without delay if they have onset of fatigue, weakness, lack of appetite,<br \/>\n      nausea and vomiting, jaundice or discolored feces. Healthcare providers<br \/>\n      should consider discontinuing ZEPATIER if ALT levels remain persistently<br \/>\n      greater than 10 times ULN. ZEPATIER should be discontinued if ALT<br \/>\n      elevation is accompanied by signs or symptoms of liver inflammation or<br \/>\n      increasing conjugated bilirubin, alkaline phosphatase, or international<br \/>\n      normalized ratio.\n    <\/p>\n<p>\n      The concomitant use of ZEPATIER with certain drugs may lead to possible<br \/>\n      clinically significant adverse reactions from greater exposure to<br \/>\n      ZEPATIER or concomitant drugs. Coadministration of ZEPATIER is not<br \/>\n      recommended with certain strong CYP3A inhibitors (e.g., ketoconazole or<br \/>\n      the cobicistat-containing regimens of<br \/>\n      elvitegravir\/cobicistat\/emtricitabine\/tenofovir [disoproxil fumarate or<br \/>\n      alafenamide]). Healthcare professionals should not exceed atorvastatin<br \/>\n      20mg\/daily or rosuvastatin 10mg\/daily when given with ZEPATIER. If<br \/>\n      ZEPATIER is given with fluvastatin, lovastatin or simvastatin,<br \/>\n      healthcare professionals should give the lowest statin dose necessary<br \/>\n      and closely monitor for statin-associated adverse events. If ZEPATIER<br \/>\n      and tacrolimus are coadministered, frequent monitoring of tacrolimus<br \/>\n      whole blood concentrations, changes in renal function and<br \/>\n      tacrolimus-associated adverse events is recommended.\n    <\/p>\n<p>\n      The concomitant use of ZEPATIER and certain drugs may cause significant<br \/>\n      decrease of elbasvir and grazoprevir plasma concentrations, which may<br \/>\n      lead to reduced therapeutic effect of ZEPATIER and possible development<br \/>\n      of resistance. Coadministration of ZEPATIER is not recommended with<br \/>\n      moderate CYP3A inducers (e.g., nafcillin, bosentan, etravirine,<br \/>\n      modafinil).\n    <\/p>\n<p>\n      In subjects receiving ZEPATIER for 12 weeks, the most commonly reported<br \/>\n      adverse reactions of all intensity (greater than or equal to 5% in<br \/>\n      placebo-controlled trials) were fatigue, headache and nausea. In<br \/>\n      subjects receiving ZEPATIER with RBV for 16 weeks, the most commonly<br \/>\n      reported adverse reactions of moderate or severe intensity (greater than<br \/>\n      or equal to 5%) were anemia and headache.\n    <\/p>\n<p>\n      <b>About ZEPATIER\u2122 (elbasvir and grazoprevir) 50mg\/100mg Tablets<\/b>\n    <\/p>\n<p>\n      ZEPATIER is a fixed-dose combination product containing elbasvir, a<br \/>\n      hepatitis C virus (HCV) NS5A inhibitor, and grazoprevir, an HCV NS3\/4A<br \/>\n      protease inhibitor, and is indicated with or without ribavirin (RBV) for<br \/>\n      treatment of chronic HCV genotype (GT) 1 or GT4 infection in adults. The<br \/>\n      dosing regimens and durations for treatment with once-daily ZEPATIER for<br \/>\n      chronic HCV GT1 or GT4 infection in patients with or without cirrhosis,<br \/>\n      HIV-1 co-infection or renal impairment are as follows:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Twelve weeks of treatment with ZEPATIER is recommended for:<br \/>\n        GT1a-infected patients who are treatment-na\u00efve or who failed prior<br \/>\n        treatment with peginterferon alfa plus RBV (PegIFN\/RBV-experienced)<br \/>\n        without baseline NS5A resistance-associated polymorphisms (amino acid<br \/>\n        positions 28, 30, 31 or 93); GT1b-infected patients who are<br \/>\n        treatment-na\u00efve or PegIFN\/RBV-experienced; and GT4-infected patients<br \/>\n        who are treatment-na\u00efve.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Twelve weeks of&nbsp;treatment with ZEPATIER in combination with RBV is<br \/>\n        recommended for GT1a- or GT1b-infected patients who failed prior<br \/>\n        treatment with PegIFN\/RBV + a HCV NS3\/4A protease inhibitor (PI)<br \/>\n        (boceprevir, simeprevir or telaprevir).&nbsp;For GT1a-infected<br \/>\n        PegIFN\/RBV\/PI-experienced patients with one or more baseline NS5A<br \/>\n        resistance-associated polymorphisms, the optimal ZEPATIER-based<br \/>\n        treatment regimen and duration of therapy has not been established.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Sixteen weeks of treatment with ZEPATIER in combination with RBV is<br \/>\n        recommended for: GT1a-infected patients who are treatment-na\u00efve or<br \/>\n        PegIFN\/RBV-experienced with baseline NS5A resistance-associated<br \/>\n        polymorphisms;<sup> <\/sup>and GT4-infected patients who are<br \/>\n        PegIFN\/RBV-experienced.\n      <\/li>\n<\/ul>\n<p>\n      For patients with chronic HCV GT1a infection, testing for the presence<br \/>\n      of NS5A resistance-associated polymorphisms is recommended prior to<br \/>\n      starting treatment with ZEPATIER to determine the optimal dosage regimen<br \/>\n      and duration.\n    <\/p>\n<p>\n      <b>Merck\u2019s Commitment to HCV<\/b>\n    <\/p>\n<p>\n      For nearly 30 years, Merck has been at the forefront of the response to<br \/>\n      the HCV epidemic. Merck employees are dedicated to applying their<br \/>\n      scientific expertise, resources and global reach to develop and deliver<br \/>\n      innovative healthcare solutions to support people living with chronic<br \/>\n      HCV worldwide.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51309121&amp;newsitemid=20160330005116&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=14&amp;md5=e97fc85752afe72b4f13bc6b471c582c\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51309121&amp;newsitemid=20160330005116&amp;lan=en-US&amp;anchor=Twitter&amp;index=15&amp;md5=3e524875911d7d9bd1194b164e74c296\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51309121&amp;newsitemid=20160330005116&amp;lan=en-US&amp;anchor=Facebook&amp;index=16&amp;md5=6454e447499fbc53cba17f1cbc663a4d\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51309121&amp;newsitemid=20160330005116&amp;lan=en-US&amp;anchor=YouTube&amp;index=17&amp;md5=f53224d6b8aed528599726395418f707\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51309121&amp;newsitemid=20160330005116&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=18&amp;md5=1b0653c2e627bda8729154a15fdee2c6\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51309121&amp;newsitemid=20160330005116&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=19&amp;md5=10d7d9d4febaaaddd965ef31cc9e6c04\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for ZEPATIER (elbasvir and<br \/>\n      grazoprevir) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzepatier%2Fzepatier_pi.pdf&amp;esheet=51309121&amp;newsitemid=20160330005116&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzepatier%2Fzepatier_pi.pdf&amp;index=20&amp;md5=4f17077056a08c24956624c6dd3cc0dc\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/z\/zepatier\/zepatier_pi.pdf<\/b><\/a><b><br \/>\n      and the Patient Information for ZEPATIER at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzepatier%2Fzepatier_ppi.pdf&amp;esheet=51309121&amp;newsitemid=20160330005116&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzepatier%2Fzepatier_ppi.pdf&amp;index=21&amp;md5=2243a44f2c69f3e4bd31f09cc6cd2b30\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/z\/zepatier\/zepatier_ppi.pdf<\/b><\/a><b>.<\/b>\n    <\/p>\n<p>\n      _____________\n    <\/p>\n<p>\n      <sup>1<\/sup> MK-8408 is an HCV NS5A inhibitor\n    <\/p>\n<p>\n      <sup>2<\/sup> MK-3682 is an HCV nucleotide analogue NS5B polymerase<br \/>\n      inhibitor\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20160330005116r2&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>Sarra Herzog,        908-740-1871<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>Amy        Klug, 908-740-1898<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the planned presentations of data from the company\u2019s broad chronic hepatitis C virus (HCV) clinical development programs at the upcoming International Liver Congress\u2122 2016 . Clinical data from trials evaluating ZEPATIER\u2122 (elbasvir and grazoprevir) 50mg\/100mg tablets will be featured, including the Phase 3 C-EDGE Head-to-Head trial comparing ZEPATIER to a regimen of sofosbuvir with peginterferon alfa and ribavirin (RBV), and the Phase 3 C-EDGE IBLD and C-EDGE CO-STAR studies evaluating ZEPATIER in underserved patients with historically difficult-to-treat conditions. In addition, data from trials evaluating Merck\u2019s chronic HCV candidates MK-3682B (grazoprevir\/MK-8408 1 \/MK-3682 2 ) and MK-8408 monotherapy will be presented. ZEPATIER \u2013 Merck\u2019s once-daily, fixed-dose combination tablet indicated with or without RBV for the treatment of chronic HCV genotype (GT) 1 or GT4 infection in adults \u2013 was<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,140,141,64,289,56],"class_list":["post-745401","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-hepatitis-c","tag-hepatitis-c-newsroom","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck to Present New Findings from Chronic Hepatitis C Clinical Development Programs at The International Liver CongressTM 2016 - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-findings-from-chronic-hepatitis-c-clinical-development-programs-at-the-international-liver-congresstm-2016\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck to Present New Findings from Chronic Hepatitis C Clinical Development Programs at The International Liver CongressTM 2016 - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the planned presentations of data from the company\u2019s broad chronic hepatitis C virus (HCV) clinical development programs at the upcoming International Liver Congress\u2122 2016 . Clinical data from trials evaluating ZEPATIER\u2122 (elbasvir and grazoprevir) 50mg\/100mg tablets will be featured, including the Phase 3 C-EDGE Head-to-Head trial comparing ZEPATIER to a regimen of sofosbuvir with peginterferon alfa and ribavirin (RBV), and the Phase 3 C-EDGE IBLD and C-EDGE CO-STAR studies evaluating ZEPATIER in underserved patients with historically difficult-to-treat conditions. In addition, data from trials evaluating Merck\u2019s chronic HCV candidates MK-3682B (grazoprevir\/MK-8408 1 \/MK-3682 2 ) and MK-8408 monotherapy will be presented. ZEPATIER \u2013 Merck\u2019s once-daily, fixed-dose combination tablet indicated with or without RBV for the treatment of chronic HCV genotype (GT) 1 or GT4 infection in adults \u2013 was\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-findings-from-chronic-hepatitis-c-clinical-development-programs-at-the-international-liver-congresstm-2016\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-findings-from-chronic-hepatitis-c-clinical-development-programs-at-the-international-liver-congresstm-2016\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-findings-from-chronic-hepatitis-c-clinical-development-programs-at-the-international-liver-congresstm-2016\\\/\",\"name\":\"Merck to Present New Findings from Chronic Hepatitis C Clinical Development Programs at The International Liver CongressTM 2016 - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-03-30T06:00:00+00:00\",\"dateModified\":\"2025-11-07T06:25:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-findings-from-chronic-hepatitis-c-clinical-development-programs-at-the-international-liver-congresstm-2016\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-findings-from-chronic-hepatitis-c-clinical-development-programs-at-the-international-liver-congresstm-2016\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-findings-from-chronic-hepatitis-c-clinical-development-programs-at-the-international-liver-congresstm-2016\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck to Present New Findings from Chronic Hepatitis C Clinical Development Programs at The International Liver CongressTM 2016\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck to Present New Findings from Chronic Hepatitis C Clinical Development Programs at The International Liver CongressTM 2016 - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-findings-from-chronic-hepatitis-c-clinical-development-programs-at-the-international-liver-congresstm-2016\/","og_locale":"en_US","og_type":"article","og_title":"Merck to Present New Findings from Chronic Hepatitis C Clinical Development Programs at The International Liver CongressTM 2016 - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the planned presentations of data from the company\u2019s broad chronic hepatitis C virus (HCV) clinical development programs at the upcoming International Liver Congress\u2122 2016 . Clinical data from trials evaluating ZEPATIER\u2122 (elbasvir and grazoprevir) 50mg\/100mg tablets will be featured, including the Phase 3 C-EDGE Head-to-Head trial comparing ZEPATIER to a regimen of sofosbuvir with peginterferon alfa and ribavirin (RBV), and the Phase 3 C-EDGE IBLD and C-EDGE CO-STAR studies evaluating ZEPATIER in underserved patients with historically difficult-to-treat conditions. In addition, data from trials evaluating Merck\u2019s chronic HCV candidates MK-3682B (grazoprevir\/MK-8408 1 \/MK-3682 2 ) and MK-8408 monotherapy will be presented. ZEPATIER \u2013 Merck\u2019s once-daily, fixed-dose combination tablet indicated with or without RBV for the treatment of chronic HCV genotype (GT) 1 or GT4 infection in adults \u2013 was","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-findings-from-chronic-hepatitis-c-clinical-development-programs-at-the-international-liver-congresstm-2016\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:56+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-findings-from-chronic-hepatitis-c-clinical-development-programs-at-the-international-liver-congresstm-2016\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-findings-from-chronic-hepatitis-c-clinical-development-programs-at-the-international-liver-congresstm-2016\/","name":"Merck to Present New Findings from Chronic Hepatitis C Clinical Development Programs at The International Liver CongressTM 2016 - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-03-30T06:00:00+00:00","dateModified":"2025-11-07T06:25:56+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-findings-from-chronic-hepatitis-c-clinical-development-programs-at-the-international-liver-congresstm-2016\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-findings-from-chronic-hepatitis-c-clinical-development-programs-at-the-international-liver-congresstm-2016\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-findings-from-chronic-hepatitis-c-clinical-development-programs-at-the-international-liver-congresstm-2016\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck to Present New Findings from Chronic Hepatitis C Clinical Development Programs at The International Liver CongressTM 2016"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"990c0a6c-c125-43ea-aa4a-7c477fe87e10","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-to-Present-New-Findings-from-Chronic-Hepatitis-C-Clinical-Development-Programs-at-The-International-Liver-CongressTM-2016-2016.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745401","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745401\/revisions"}],"predecessor-version":[{"id":3674795,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745401\/revisions\/3674795"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745401"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745401"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}